Edoxaban (Savaysa): A Factor Xa Inhibitor

Lewey Chan et al. P T. 2015 Oct.

. 2015 Oct;40(10):651-95.

Erratum in

Correction.
[No authors listed] [No authors listed] P T. 2015 Dec;40(12):808. P T. 2015. PMID: 26681902 Free PMC article.

Edoxaban (Savaysa): A factor Xa inhibitor

1. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–1539. - PubMed
1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation. Circulation. 2004;110(9):1042–1046. - PubMed
1. Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15–e16. - PubMed
1. January CT, Wann L, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):2246–2280. - PubMed
1. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e531S–e575S. - PMC - PubMed